Abera Bioscience AB

Abera Bioscience is active in biotechnology. The company specializes in the development of vaccines based on its own internal developed and patented platform. The technology is mainly used in the development of new vaccines where the focus is on the main areas of pneumococci and oncology. The business is located around the Nordic market. The company was founded in 2012 and is headquartered in Solna.

Quotes for Abera Bioscience AB

Created with Highstock 6.0.7CloseTraded Volume3. mar10. mar17. mar24. mar31. mar7. apr21. apr28. apr5. maj12. maj19. maj26. maj036912020T40T60T80T

Right Now

+/-
-0.25
%
−3,31%
Latest
7.3
High
7.95
Low
7.3
Volume
7 535
Turnover (SEK)
56 492
Market Value (MSEK)
112,1
Time (Latest trade)
2025-05-27 17:19

Board

CEO

  • Maria Alriksson

Chairperson of the Board

  • Anders Ericsson

Board

  • Cristina Glad
  • Fredrik Juserius
  • Harry Råstedt
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    Abera's vaccine platform BERA - short explanation

    Abera's vaccine platform BERA - short explanation

    Abera's vaccine platform BERA - short explanation

    Abera's vaccine platform BERA - short explanation

    Abera's vaccine platform BERA - short explanation

    Largest Owners

    Name Capital % Votes % Date
    Avanza Pension 12,66 12,66 2025-03-27
    Nordnet Pensionsförsäkring 8,07 8,07 2025-03-27
    Anders Ericsson 4,06 4,06 2025-03-27
    Jan-Willem De Gier 3,88 3,88 2025-03-27
    Joen Luirink 3,80 3,80 2025-03-27
    Stefan Olsson 3,51 3,51 2025-03-27
    Anders Wall stiftelser 2,09 2,09 2025-03-27
    Handelsbanken Liv Försäkring AB 2,07 2,07 2025-03-27
    Maths Wahlström 2,03 2,03 2025-03-27
    Agneta Albinsson 2,03 2,03 2025-03-27
    ** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

    Insider trading

    NameTransaction DateTypeInstrumentAmountPriceValueCurrency
    Mats Lundgren2022-05-18Buy TransactionSpotlight Group 3 8239,5936 662,6SEK
    Mats Lundgren2022-05-17Buy TransactionAbera Bioscience 8568,297 096,2SEK
    Mats Lundgren2022-05-16Buy TransactionAbera Bioscience 6 5357,951 626,5SEK
    Mats Lundgren2022-05-13Buy TransactionAbera Bioscience 7 0008,0256 140,0SEK
    Mats Lundgren2022-05-13Buy TransactionAbera Bioscience 6 0008,0148 060,0SEK
    Anders Ericsson2022-05-13Buy TransactionAbera Bioscience 2 0007,9315 860,0SEK
    Anders Ericsson2022-05-13Buy TransactionAbera Bioscience 2 0007,9315 860,0SEK
    Anders Ericsson2022-05-17Buy TransactionAbera Bioscience 8788,57 463,0SEK
    Anders Ericsson2022-05-16Buy TransactionAbera Bioscience 6 0008,249 200,0SEK
    Cristina Glad2022-05-12Buy TransactionAbera Bioscience 6 0007,9847 880,0SEK
    Anders Ericsson2022-01-20Buy TransactionAbera Bioscience 12 00015,58186 960,0SEK
    *Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

    Key Numbers

    2025-03-312024-12-312024-12-312024-09-302024-06-302024-03-312023-12-31
    Number of months that the report spans Q1 3 Months2024Q4 3 MonthsQ3 3 MonthsQ2 3 MonthsQ1 3 Months2023
    Total revenue MSEK0.000.000.000.000.000.000.00
    Earnings before interest and tax MSEK0.00-1.120.18-0.28-0.66-0.36-16.80
    Profit before tax MSEK0.01-1.100.20-0.28-0.67-0.36-16.72
    Net profit MSEK0.01-1.100.20-0.28-0.67-0.36-16.72
    Earnings per share SEK0.00-0.000.00-0.00-0.00-0.00-0.00
    Dividend per share SEK0.000.00
    Equity MSEK8.678.668.668.528.809.275.66
    Fixed assets MSEK1.031.071.070.410.410.000.00
    Intangible assets MSEK1.891.891.891.881.891.891.89
    Current assets MSEK8.7210.6510.657.598.819.837.46
    Total asset MSEK11.6413.6013.609.8911.1011.729.35
    Long term liabilities MSEK0.000.000.000.000.000.000.00
    Current liabilities MSEK2.974.954.951.372.302.453.69
    Number of shares SEK15.3515.3515.3515.3515.3514.4614.46
    *Compiled data from Millistream

    Upcoming reports

    • 2025-06-11 Årsstämma 2024

    • 2025-08-21 Delårsrapport 2025-Q2

    • 2025-11-13 Delårsrapport 2025-Q3

    • 2026-02-12 Bokslutskommuniké 2025

    Annual reports, prospectus etc.